Aurinia Pharmaceuticals (AUPH) EBITDA (2019 - 2026)
Aurinia Pharmaceuticals' (AUPH) quarterly EBITDA came in at $41.4 million in Q1 2026, up 89.6% YoY from $21.8 million in Q1 2025, and up 24.62% on a QoQ basis from $33.2 million in Q4 2025.
Aurinia Pharmaceuticals (AUPH) EBITDA (2019 - 2026) Analysis & Trends
Aurinia Pharmaceuticals (AUPH) has 8 years of EBITDA data on file, last reported at $41.4 million in Q1 2026.
- Quarterly EBITDA rose 89.6% year-over-year to $41.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $124.5 million (up 309.33% YoY) and the FY2025 annual result came in at $104.9 million, up 2338.4% from the prior year.
- EBITDA climbed to $41.4 million in Q1 2026, from $33.2 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $41.4 million in Q1 2026 to a low of -$37.9 million in Q1 2022.
- A 5-year average of -$3.6 million and a median of -$9.5 million in 2022 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2023 — EBITDA slumped 71.21% — and 2025, when it surged 2091.55%.
- Tracing AUPH's EBITDA over 5 years: stood at -$28.1 million in 2022, then fell by 5.6% to -$29.7 million in 2023, then surged by 94.38% to -$1.7 million in 2024, then surged by 2091.55% to $33.2 million in 2025, then grew by 24.62% to $41.4 million in 2026.
- The last three EBITDA figures came in at $41.4 million (Q1 2026), $33.2 million (Q4 2025), and $29.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Aurinia Pharmaceuticals | 2.06 Bn | 1.61 Bn | 76.67 Mn | 46.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 46.34 Mn |
| Mar 31, 2026 | 41.42 Mn |
| Dec 31, 2025 | 33.24 Mn |
| Sep 30, 2025 | 29.75 Mn |
| Jun 30, 2025 | 20.08 Mn |
| Mar 31, 2025 | 21.85 Mn |
| Dec 31, 2024 | -1.67 Mn |
| Sep 30, 2024 | 11.75 Mn |
| Jun 30, 2024 | -1.51 Mn |
| Mar 31, 2024 | -13.25 Mn |
| Dec 31, 2023 | -29.67 Mn |
| Sep 30, 2023 | -16.26 Mn |
| Jun 30, 2023 | -16.17 Mn |
| Mar 31, 2023 | -29.58 Mn |
| Dec 31, 2022 | -28.10 Mn |
| Sep 30, 2022 | -9.50 Mn |
| Jun 30, 2022 | -35.99 Mn |
| Mar 31, 2022 | -37.88 Mn |
| Dec 31, 2021 | -32.71 Mn |
| Sep 30, 2021 | -50.35 Mn |